Consensus recommendation for the treatment of generalised Myasthenia Gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain

Abstract

Myasthenia Gravis (MG) is a rare, chronic, and autoimmune neuromuscular disease caused by presence of pathogenic immunoglobulins G (IgG) targeting postsynaptic components of the neuromuscular junction resulting in muscle weakness and fatigability. Currently therapies for MG are focused on improving clinical symptoms aiming to achieve remission or minimal expression of symptoms. Immunologically, 85 % of patients with generalised MG (gMG) have autoantibodies against the acetylcholine receptor (AChR+). In Spain, several reviews on MG treatment have been published, but the approval of new molecules with more targeted mechanisms of action indicated for gMG AChR+ makes necessary to update the current treatment protocol to reflect the latest evidence and align it with current recommendations from national and international clinical practice.